000169899 001__ 169899
000169899 005__ 20240229133659.0
000169899 0247_ $$2doi$$a10.1136/bmjopen-2020-047277
000169899 0247_ $$2pmid$$apmid:34281921
000169899 0247_ $$2ISSN$$a2044-6055
000169899 0247_ $$2ISSN$$a2053-3624
000169899 0247_ $$2ISSN$$a2398-595X
000169899 0247_ $$2altmetric$$aaltmetric:110115898
000169899 037__ $$aDKFZ-2021-01633
000169899 041__ $$aEnglish
000169899 082__ $$a610
000169899 1001_ $$00000-0003-3628-9056$$aSauer, Christina$$b0
000169899 245__ $$aeHealth intervention to manage symptoms for patients with cancer on immunotherapy (SOFIA): a study protocol for a randomised controlled external pilot trial.
000169899 260__ $$aLondon$$bBMJ Publishing Group$$c2021
000169899 3367_ $$2DRIVER$$aarticle
000169899 3367_ $$2DataCite$$aOutput Types/Journal article
000169899 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1627464551_3141
000169899 3367_ $$2BibTeX$$aARTICLE
000169899 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169899 3367_ $$00$$2EndNote$$aJournal Article
000169899 520__ $$aImmune checkpoint therapy (ICT) is associated with a distinct pattern of immune-related adverse events (irAEs) caused by inadvertently redirecting immune responses to healthy tissues. IrAEs can occur at any time; however, in most cases, they arise during the first 14 weeks of the beginning of immune checkpoint blockade. In many cases, immunotherapy must be discontinued due to irAEs. Early detection of irAEs triggers the temporary withholding of ICT or initiation of short-term immunosuppressive treatment, is crucial in preventing further aggravation of irAEs and enables safe re-exposure to ICT. This prospective study aims to evaluate the feasibility of an eHealth intervention for patients under immunotherapy (managing symptoms of immunotherapy, SOFIA). The SOFIA-App consists of two components: SOFIA-Monitoring, a tool to rate patient-reported outcomes (PROs) including irAEs, and SOFIA-Coaching, which provides important information about cancer-specific and immunotherapy-specific topics and the counselling services of the National Centre for Tumour Diseases (NCT) Heidelberg.We outlined a patient-level two-arm randomised controlled pilot trial of the intervention (SOFIA) versus no-SOFIA for patients with cancer beginning an immunotherapy, aged ≥18 years, recruited from the NCT, Heidelberg. Feasibility outcomes include: recruitment rate; drop-out rate; reasons for refusal and drop-out; willingness to be randomised, utilisation rate of SOFIA-Monitoring and utilisation time of SOFIA-Coaching, physicians utilisation rate of the PROs; feasibility of the proposed outcome measures and optimal sample size estimation. The clinical outcomes are measures of quality of life, psychosocial symptoms, self-efficacy, physician-patient communication and medical process data, which are assessed at the beginning of the intervention, postintervention and at 6-month follow-up.This trial protocol was approved by the Ethical Committee of Heidelberg University, Germany (Reference, S-581/2018).We registered the study in the German Clinical Trial Register (Reference: DRKS00021064). Findings will be disseminated broadly via peer-reviewed empirical journals, articles and conference presentations.
000169899 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169899 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169899 650_7 $$2Other$$aadverse events
000169899 650_7 $$2Other$$amental health
000169899 650_7 $$2Other$$aoncology
000169899 7001_ $$aKrauß, Jürgen$$b1
000169899 7001_ $$aJäger, Dirk$$b2
000169899 7001_ $$aZschäbitz, Stefanie$$b3
000169899 7001_ $$aHaag, Georg Martin$$b4
000169899 7001_ $$0P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aWalle, Thomas$$b5$$udkfz
000169899 7001_ $$aSauer, Simeon$$b6
000169899 7001_ $$aKiermeier, Senta$$b7
000169899 7001_ $$aFriederich, Hans-Christoph$$b8
000169899 7001_ $$00000-0002-8030-1182$$aMaatouk, Imad$$b9
000169899 773__ $$0PERI:(DE-600)2599832-8$$a10.1136/bmjopen-2020-047277$$gVol. 11, no. 7, p. e047277 -$$n7$$pe047277$$tBMJ open$$v11$$x2044-6055$$y2021
000169899 909CO $$ooai:inrepo02.dkfz.de:169899$$pVDB
000169899 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169899 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169899 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000169899 9141_ $$y2021
000169899 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000169899 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000169899 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000169899 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000169899 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000169899 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000169899 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000169899 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ
000169899 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000169899 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000169899 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000169899 9201_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000169899 980__ $$ajournal
000169899 980__ $$aVDB
000169899 980__ $$aI:(DE-He78)F230-20160331
000169899 980__ $$aUNRESTRICTED